MicroRNA-206 prevents hepatosteatosis and hyperglycemia by facilitating insulin signaling and impairing lipogenesis

Journal of Hepatology

Volumn 66, Issue 4, 2017, Pages 816-824

  Wu, Heng ^a   Zhang, Tianpeng ^a   Pan, Fei ^a   Steer, Clifford J ^a,b   Li, Zhuoyu ^c   Chen, Xin ^d   Song, Guisheng ^a,b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c SHANXI UNIVERSITY   (China)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Diet, high fat; Hyperglycemia; Insulin signaling; Lipogenesis; MicroRNAs; NAFLD; Phosphorylation

Indexed keywords

INSULIN; INSULIN RECEPTOR; LIPID; MICRORNA; MICRORNA 206; PROTEIN TYROSINE PHOSPHATASE 1B; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; UNCLASSIFIED DRUG; MIRN206 MICRORNA, HUMAN; MIRN206 MICRORNA, MOUSE; PTPN1 PROTEIN, HUMAN; PTPN1 PROTEIN, MOUSE; SREBF1 PROTEIN, MOUSE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

3' UNTRANSLATED REGION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOGENESIS; CONTROLLED STUDY; FATTY LIVER; GLUCONEOGENESIS; HUMAN; HUMAN CELL; HYPERGLYCEMIA; LIPID DIET; LIPID STORAGE; LIPOGENESIS; LIVER CELL; MALE; MOUSE; NONHUMAN; OBESITY; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; ANIMAL; C57BL MOUSE; GENETICS; HEP-G2 CELL LINE; INSULIN RESISTANCE; LIVER; METABOLISM; NONALCOHOLIC FATTY LIVER; SIGNAL TRANSDUCTION;

3' UNTRANSLATED REGIONS; ANIMALS; DIET, HIGH-FAT; HEP G2 CELLS; HEPATOCYTES; HUMANS; HYPERGLYCEMIA; INSULIN; INSULIN RESISTANCE; LIPOGENESIS; LIVER; MALE; MICE; MICE, INBRED C57BL; MICRORNAS; NON-ALCOHOLIC FATTY LIVER DISEASE; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 1; SIGNAL TRANSDUCTION; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

EID: 85010520710     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2016.12.016     Document Type: Article

References (38)

1. [1] Nath, D., Heemels, M.-T., Anson, L., Obesity and diabetes. Nature 444 (2006), 839–888.
2. [2] Postic, C., Pathogenesis of fatty liver disease. Endocr Abstracts, 29, 2012, S55.
3. [3] Gaggini, M., Morelli, M., Buzzigoli, E., DeFronzo, R.A., Bugianesi, E., Gastaldelli, A., Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients 5 (2013), 1544–1560.
4. [4] Xiao, X., Song, B.-L., SREBP: a novel therapeutic target. Acta Biochim Biophys Sin 45 (2013), 2–10.
5. [5] Ferre, P., Foufelle, F., Hepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP-1c. Diabetes Obes Metab 12 (2010), 83–92.
6. [6] Bartel, D., MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116 (2004), 281–297.
7. [7] Ng, R., Wu, H., Xiao, H., Chen, X., Willenbring, H., Steer, C.J., et al. Inhibition of microRNA-24 expression in liver prevents hepatic lipid accumulation and hyperlipidemia. Hepatology 60 (2014), 554–564.
8. [8] Hayes, J., Peruzzi, P.P., Lawler, S., MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol Med 20 (2014), 460–469.
9. [9] Cheung, O., Puri, P., Eicken, C., Contos, M.J., Mirshahi, F., Maher, J.W., et al. Nonalcoholic steatohepatitis is associated with altered hepatic microRNA expression. Hepatology 48 (2008), 1810–1820.
10. [10] Ferland-McCollough, D., Ozanne, S.E., Siddle, K., Willis, A.E., Bushell, M., The involvement of microRNAs in type 2 diabetes. Biochem Soc Trans 38 (2010), 1565–1570.
11. [11] Vickers, K.C., Shoucri, B.M., Levin, M.G., Wu, H., Pearson, D.S., Osei-Hwedieh, D., et al. MicroRNA-27b is a regulatory hub in lipid metabolism and is altered in dyslipidemia. Hepatology 57 (2013), 533–542.
12. [12] Jayandharan, G.R., Zhong, L., Sack, B.K., Rivers, A.E., Li, M., Li, B., et al. Optimized Adeno-Associated Virus (AAV)–protein phosphatase-5 helper viruses for efficient liver transduction by single-stranded AAV vectors: therapeutic expression of factor IX at reduced vector doses. Hum Gene Ther 21 (2010), 271–283.
13. [13] Cui, W., Chen, S.L., Hu, K.-Q., Quantification and mechanisms of oleic acid-induced steatosis in HepG2 cells. Am J Transl Res 2 (2010), 95–104.
14. [14] Ito, Y., Oumi, S., Nagasawa, T., Nishizawa, N., Oxidative stress induces phosphoenolpyruvate carboxykinase expression in H4IIE cells. Biosci Biotechnol Biochem 70 (2006), 2191–2198.
15. [15] Gomez-Lechon, M.J., Donato, M.T., Martínez-Romero, A., Jiménez, N., Castell, J.V., O'Connor, J.-E., A human hepatocellular in vitro model to investigate steatosis. Chem Biol Interact 165 (2007), 106–116.
16. [16] Friedman, R., Farh, K., Burge, C., Bartel, D., Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 19 (2009), 92–105.
17. [17] Krek, A., Grün, D., Poy, M., Wolf, R., Rosenberg, L., Epstein, E., et al. Combinatorial microRNA target predictions. Nat Genet 37 (2005), 495–500.
18. [18] Yang, J.-H., Li, J.-H., Shao, P., Zhou, H., Chen, Y.-Q., Qu, L.-H., StarBase: a database for exploring microRNA–mRNA interaction maps from Argonaute CLIP-Seq and Degradome-Seq data. Nucleic Acids Res 39 (2011), D202–D209.
19. [19] Shimizu, S., Ugi, S., Maegawa, H., Egawa, K., Nishio, Y., Yoshizaki, T., et al. Protein-tyrosine phosphatase 1B as new activator for hepatic lipogenesis via sterol regulatory element-binding protein-1 gene expression. J Biol Chem 278 (2003), 43095–43101.
20. [20] Delibegovic, M., Zimmer, D., Kauffman, C., Rak, K., Hong, E.-G., Cho, Y.-R., et al. Liver-specific deletion of protein-tyrosine phosphatase 1B (PTP1B) improves metabolic syndrome and attenuates diet-induced endoplasmic reticulum stress. Diabetes 58 (2009), 590–599.
21. [21] González-Rodríguez, Á., Gutierrez, J.A.M., Sanz-González, S., Ros, M., Burks, D.J., Valverde, Á.M., Inhibition of PTP1B restores IRS1-mediated hepatic insulin signaling in IRS2-deficient mice. Diabetes 59 (2010), 588–599.
22. [22] Staton, A.A., Giraldez, A.J., Use of target protector morpholinos to analyze the physiological roles of specific miRNA-mRNA pairs in vivo. Nat Protoc 6 (2011), 2035–2049.
23. [23] Mayrhofer, P., Schleef, M., Jechlinger, W., Use of minicircle plasmids for gene therapy. Gene therapy of cancer. 2009, Springer, 87–104.
24. [24] Tao, J., Ji, J., Li, X., Ding, N., Wu, H., Liu, Y., et al. Distinct anti-oncogenic effect of various microRNAs in different mouse models of liver cancer. Oncotarget 6 (2015), 6977–6988.
25. [25] Anderson, N., Borlak, J., Molecular mechanisms and therapeutic targets in steatosis and steatohepatitis. Pharmacol Rev 60 (2008), 311–357.
26. [26] Huang, J., Jia, Y., Fu, T., Viswakarma, N., Bai, L., Rao, M.S., et al. Sustained activation of PPARα by endogenous ligands increases hepatic fatty acid oxidation and prevents obesity in ob/ob mice. FASEB J 26 (2012), 628–638.
27. [27] Kim, H.K., Lee, Y.S., Sivaprasad, U., Malhotra, A., Dutta, A., Muscle-specific microRNA miR-206 promotes muscle differentiation. J Cell Biol 174 (2006), 677–687.
28. [28] Song, G., Wang, L., Nuclear receptor SHP activates miR-206 expression via a cascade dual inhibitory mechanism. PLoS One, 4, 2009, e6880.
29. [29] Huang, J., Iqbal, J., Saha, P.K., Liu, J., Chan, L., Hussain, M.M., et al. Molecular characterization of the role of orphan receptor small heterodimer partner in development of fatty liver. Hepatology 46 (2007), 147–157.
30. [30] Tseng, H.-T., Park, Y.J., Lee, Y.K., Moore, D.D., The orphan nuclear receptor small heterodimer partner is required for thiazolidinedione effects in leptin-deficient mice. J Biomed Sci, 22, 2015, 1.
31. [31] Moore, M.J., Zhang, C., Gantman, E.C., Mele, A., Darnell, J.C., Darnell, R.B., Erratum: Mapping Argonaute and conventional RNA-binding protein interactions with RNA at single-nucleotide resolution using HITS-CLIP and CIMS analysis. Nat Protoc, 11, 2016, 616.
32. [32] Dutka, T., Sarshad, A.A., Hafner, M., PAR-CLIP: a genomic technique to dissect RNA-protein interactions. Field guidelines for genetic experimental designs in high-throughput sequencing. 2016, Springer, 261–289.
33. [33] Kondo, N., Toyama, T., Sugiura, H., Fujii, Y., Yamashita, H., MiR-206 expression is down-regulated in estrogen receptor α–positive human breast cancer. Cancer Res 68 (2008), 5004–5008.
34. [34] Yan, D., Dong, X.D.E., Chen, X., Wang, L., Lu, C., Wang, J., et al. MicroRNA-1/206 targets c-Met and inhibits rhabdomyosarcoma development. J Biol Chem 284 (2009), 29596–29604.
35. [35] Zhang, T., Liu, M., Wang, C., Lin, C., Sun, Y., Jin, D., Down-regulation of MiR-206 promotes proliferation and invasion of laryngeal cancer by regulating VEGF expression. Anticancer Res 31 (2011), 3859–3863.
36. [36] Zhong, D., Huang, G., Zhang, Y., Zeng, Y., Xu, Z., Zhao, Y., et al. MicroRNA-1 and microRNA-206 suppress LXRalpha-induced lipogenesis in hepatocytes. Cell Signal 25 (2013), 1429–1437.
37. [37] Zelcer, N., Tontonoz, P., Liver X receptors as integrators of metabolic and inflammatory signaling. J Clin Invest 116 (2006), 607–614.
38. [38] Zhao, C., Dahlman-Wright, K., Liver X receptor in cholesterol metabolism. J Endocrinol 204 (2010), 233–240.